Shenzhenlubris Pharmaceuticals Co (SZSE:002294) ROCE % : 2.68% (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shenzhenlubris Pharmaceuticals Co's annualized ROCE % for the quarter that ended in Dec. 2024 was 2.68%.

Shenzhenlubris Pharmaceuticals Co ROCE % Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co ROCE % Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

1.16

8.68

8.87

7.88

7.23

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															4.47	10.80	7.90	8.25	2.68

Shenzhenlubris Pharmaceuticals Co ROCE % Calculation

Shenzhenlubris Pharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	648.69	/	( ( (9396.673 - 815.084)	+	(10465.604 - 1112.967) )	/ 2 )
	=	648.69	/	( (8581.589	+	9352.637)	/ 2 )
	=	648.69	/	8967.113
	=	7.23 %

Shenzhenlubris Pharmaceuticals Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	248.952	/	( ( (10232.539 - 1011.02)	+	(10465.604 - 1112.967) )	/ 2 )
	=	248.952	/	( ( 9221.519	+	9352.637 )	/ 2 )
	=	248.952	/	9287.078
	=	2.68 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shenzhenlubris Pharmaceuticals Co ROCE % Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6009 Shennan Road, 37th Floor, Main Building, Chegongmiao Lvjing Plaza, Futian District, Guangdong, Shenzhen, CHN, 518040

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co Headlines

No Headlines